<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The recently identified decoy receptor 3 (DcR3) binds to FasL and inhibits FasL-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, and is considered to play a role in the immune escape system of neoplastic cells </plain></SENT>
<SENT sid="1" pm="."><plain>To examine the involvement of DcR3 in the immune evasions of virus-associated <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, we analyzed the amplification and expression of DcR3, using dot blot and in situ hybridization (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ISH</z:e>), in 45 cases, which included 17 cases with Epstein-Barr virus (EBV)-associated <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (seven <z:hpo ids='HP_0011919'>pyothorax</z:hpo>-associated B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PAL</z:e>); ten natural killer <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NKL)), seven cases with adult T-cell <z:hpo ids='HP_0001909'>leukemia</z:hpo> <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ATLL</z:e>), 13 Hodgkin's disease (eight EBV-associated cases; five non-EBV-associated cases), and eight control cases (three reactive <z:hpo ids='HP_0002716'>lymphadenopathy</z:hpo>; five non-EBV-associated-B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>) </plain></SENT>
<SENT sid="2" pm="."><plain>EBV-associated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PAL</z:e> and NKL exhibited DcR3 amplification and expression in <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ATLL</z:e> also showed DcR3 expression and amplification </plain></SENT>
<SENT sid="4" pm="."><plain>The cases with DcR3 amplification showed DcR3 expression; however, the expression was confined in the neoplastic cells, but not in the reactive cells </plain></SENT>
<SENT sid="5" pm="."><plain>In <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>), DcR3 was expressed only in Hodgkin and Reed-Sternberg giant (H-RS) cells </plain></SENT>
<SENT sid="6" pm="."><plain>However, DcR3 was not expressed or amplified in reactive <z:hpo ids='HP_0002716'>lymphadenopathy</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>Non-EBV-associated B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> also rarely expressed DcR3, and showed no amplification except in two cases, in which rare expression was present </plain></SENT>
<SENT sid="8" pm="."><plain>Our results suggest that EBV and HTLV-I probably use DcR3 to escape from the immune system during <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">lymphomagenesis</z:e>, or virus-infected <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells with DcR3 expression might be selected in the multistep <z:mp ids='MP_0002006'>tumorigenesis</z:mp> </plain></SENT>
</text></document>